-+ 0.00%
-+ 0.00%
-+ 0.00%

RACTIGEN THERAPEUTICS ANNOUNCES U.S. FDA IND CLEARANCE FOR FIRST-IN-CLASS SARNA CANDIDATE RAG-1C TO TREAT PROLIFERATIVE VITREORETINOPATHY

Reuters·07/31/2026 11:00:45

Please log in to view news